EyRIS is pleased to announce that SELENA+, a deep learning AI system designed to detect diabetic retinopathy, glaucoma-suspect and age-related macular degeneration, jointly invented by clinicians and scientists from Singapore Eye Research Institute (SERI) and NUS School of Computing has received CE Marking certification. The certification mark indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area (EEA). It is an important milestone for EyRIS as it provides access to aside from the EEA, several key markets around the world including Middle East, Africa, and Australia. SELENA+ has now both Health Science Authority (HSA) certification from Singapore and CE Mark.
They said 120,000 tests for the first year, says SGD50 per test, it will be SGD6mil, and they have 42% ,ie SGD2.7mil, or about RM9mil. However, they are the world first, and got license to market in EU, hence if the test is really that good, it will be quite significant in the coming years
Singapore government requirement is very very high one. Only world class standard only able get their contract. Novamsc show its world class abilities.
Nova MSC Bhd’s indirect subsidiary EyRIS Pte Ltd has bagged a five-year contract from Singapore’s Ministry of Health for the deployment of SELENA+, EyRIS’ first artificial intelligence (AI)-based product.
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: ES Sunlogy Berhad, a provider of mechanical and electrical (M&E) engineering services and renewable energy solutions, aims to list on the ACE Market!
MQ Trader 237 views | 1 d ago
0:17
New IPO: Techstore Berhad, an IT security and automation solutions provider, aims to list on the ACE Market!
MQ Trader 479 views | 3 d ago
0:17
New IPO: Richtech Digital Berhad, a distributor of electronic reloads and digital payment solutions, aims to list on the ACE Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Clement Ting
29 posts
Posted by Clement Ting > 2020-09-07 20:35 | Report Abuse
EyRIS is pleased to announce that SELENA+, a deep learning AI system designed to detect diabetic retinopathy, glaucoma-suspect and age-related macular degeneration, jointly invented by clinicians and scientists from Singapore Eye Research Institute (SERI) and NUS School of Computing has received CE Marking certification. The certification mark indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area (EEA). It is an important milestone for EyRIS as it provides access to aside from the EEA, several key markets around the world including Middle East, Africa, and Australia. SELENA+ has now both Health Science Authority (HSA) certification from Singapore and CE Mark.